Tokyo, Japan, January 23, 2014 — Kyowa Hakko Kirin Co., Ltd. (President and CEO: Nobuo Hanai, “Kyowa Hakko Kirin”) announced today that NESP® Injection 5μg Plastic Syringe will be launched in Japan January 24, 2014 as an additional formulation.
NESP®, a long-acting erythropoiesis stimulating agent, was initially approved in July 2007. NESP® is highly recognized for its safety and efficacy for treating anemia of adult chronic kidney disease patients on / not on dialysis and is widely used in various medical institutions. The additional indication of pediatric renal anemia was approved on September 13, 2013 in Japan, allowing NESP® to be used in renal anemia in pediatric and adult patients with chronic kidney disease.
The Launch of NESP® Injection 5μg Plastic Syringe enables expansion of NESP line-up. With the launch, we believe and hope to contribute to meticulous, individually-targeted therapy of the patients suffering from anemia of chronic kidney disease.
Kyowa Hakko Kirin is focusing on kidney area, along with three other focused areas as our category-based strategy*. With a variety kinds of products, Kyowa Hakko Kirin will contribute for kidney diseases.
* Category-based strategy: Each category (Nephrology; Oncology; Immunology and allergy; and Central Nervous System) will have its own portfolio management from R&D through to sales. We will achieve sustained growth while striving to improve productivity.
